NYSE:AMRX

Amneal Pharmaceuticals Stock Forecast, Price & News

$5.23
-0.03 (-0.57 %)
(As of 06/23/2021 02:23 PM ET)
Add
Compare
Today's Range
$5.19
$5.28
50-Day Range
$5.20
$6.02
52-Week Range
$3.45
$7.45
Volume4,780 shs
Average Volume1.53 million shs
Market Capitalization$1.57 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.26
30 days | 90 days | 365 days | Advanced Chart
Receive AMRX News and Ratings via Email

Sign-up to receive the latest news and ratings for Amneal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Amneal Pharmaceuticals logo

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates in three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products primarily for central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers licensed, owned, niche, and mature branded products, as well as Rytary for the treatment of Parkinson's disease; Zomig for the treatment of migraine headaches; Emverm a chewable tablets for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is based in Bridgewater, New Jersey.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.62 out of 5 stars

Medical Sector

422nd out of 2,105 stocks

Pharmaceutical Preparations Industry

198th out of 832 stocks

Analyst Opinion: 3.4Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 2.5 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Amneal Pharmaceuticals (NYSE:AMRX) Frequently Asked Questions

Is Amneal Pharmaceuticals a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amneal Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Amneal Pharmaceuticals stock.
View analyst ratings for Amneal Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Amneal Pharmaceuticals?

Wall Street analysts have given Amneal Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Amneal Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Amneal Pharmaceuticals' next earnings date?

Amneal Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Amneal Pharmaceuticals
.

How were Amneal Pharmaceuticals' earnings last quarter?

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) announced its earnings results on Thursday, May, 6th. The company reported $0.20 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.18 by $0.02. The firm earned $493.10 million during the quarter, compared to analysts' expectations of $514.73 million. Amneal Pharmaceuticals had a positive trailing twelve-month return on equity of 48.85% and a negative net margin of 0.87%. Amneal Pharmaceuticals's quarterly revenue was down 1.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.20 earnings per share.
View Amneal Pharmaceuticals' earnings history
.

How has Amneal Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Amneal Pharmaceuticals' stock was trading at $3.25 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AMRX stock has increased by 61.2% and is now trading at $5.24.
View which stocks have been most impacted by COVID-19
.

What guidance has Amneal Pharmaceuticals issued on next quarter's earnings?

Amneal Pharmaceuticals issued an update on its FY 2021 earnings guidance on Friday, May, 28th. The company provided EPS guidance of 0.700-0.850 for the period, compared to the Thomson Reuters consensus estimate of $0.780. The company issued revenue guidance of $2.10 billion-$2.20 billion, compared to the consensus revenue estimate of $2.14 billion.

What price target have analysts set for AMRX?

5 brokerages have issued 1 year target prices for Amneal Pharmaceuticals' shares. Their forecasts range from $5.50 to $9.00. On average, they expect Amneal Pharmaceuticals' stock price to reach $7.40 in the next year. This suggests a possible upside of 41.2% from the stock's current price.
View analysts' price targets for Amneal Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Amneal Pharmaceuticals' key executives?

Amneal Pharmaceuticals' management team includes the following people:
  • Mr. Chirag K. Patel, Co-Founder, Co-CEO, Pres & Director (Age 54, Pay $22.04k)
  • Mr. Chintu Patel R.Ph., R.Ph, Co-Founder, Co-CEO & Director (Age 49, Pay $29.85k)
  • Mr. Anastasios G. Konidaris, Exec. VP & CFO (Age 54, Pay $856.85k)
  • Ms. Nikita Shah, Exec. VP and Chief HR Officer & Strategic Planning Officer (Age 43, Pay $720.52k)
  • Mr. Joseph Todisco MBA, Exec. VP & Chief Commercial Officer of Specialty (Age 45, Pay $790.12k)
  • Mr. Andrew S. Boyer, Exec. VP & Chief Commercial Officer of Generics (Age 55, Pay $1.15M)
  • Mr. Anthony DiMeo, Sr. Director of Investor Relations
  • Mr. Stephen J. Manzano, Sr. VP, Gen. Counsel & Corp. Sec. (Age 56)
  • Mr. Sanjiv Patel, Sr. VP of Operations
  • Dr. Nikunj Patel, Head of Ops & Exec. VP of Amneal Pharmaceuticals (India) Pvt Ltd

What is Chirag and Chintu Patel's approval rating as Amneal Pharmaceuticals' CEO?

23 employees have rated Amneal Pharmaceuticals CEO Chirag and Chintu Patel on Glassdoor.com. Chirag and Chintu Patel has an approval rating of 91% among Amneal Pharmaceuticals' employees. This puts Chirag and Chintu Patel in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Amneal Pharmaceuticals' key competitors?

What other stocks do shareholders of Amneal Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amneal Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Teva Pharmaceutical Industries (TEVA), Cisco Systems (CSCO), Micron Technology (MU), General Electric (GE), OPKO Health (OPK), Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV) and Bausch Health Companies (BHC).

What is Amneal Pharmaceuticals' stock symbol?

Amneal Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "AMRX."

Who are Amneal Pharmaceuticals' major shareholders?

Amneal Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (2.56%), Eversept Partners LP (1.59%), Neuberger Berman Group LLC (1.15%), Point72 Asset Management L.P. (0.97%), Nuveen Asset Management LLC (0.77%) and Geode Capital Management LLC (0.61%). Company insiders that own Amneal Pharmaceuticals stock include Andrew S Boyer, Chintu Patel, Chirag K Patel, Gautam Patel, International Ltd Fosun, Jeffrey P George, John Kiely, Joseph Todisco, Paul M Meister, Pradeep Bhadauria and Ted C Nark.
View institutional ownership trends for Amneal Pharmaceuticals
.

Which institutional investors are selling Amneal Pharmaceuticals stock?

AMRX stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Neuberger Berman Group LLC, Globeflex Capital L P, Bank of New York Mellon Corp, Northern Trust Corp, Federated Hermes Inc., Morgan Stanley, and Prudential Financial Inc..
View insider buying and selling activity for Amneal Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Amneal Pharmaceuticals stock?

AMRX stock was purchased by a variety of institutional investors in the last quarter, including Eversept Partners LP, Point72 Asset Management L.P., Nuveen Asset Management LLC, Victory Capital Management Inc., Caas Capital Management LP, Jupiter Asset Management Ltd., Hillsdale Investment Management Inc., and Arrowstreet Capital Limited Partnership. Company insiders that have bought Amneal Pharmaceuticals stock in the last two years include Andrew S Boyer, Chintu Patel, Chirag K Patel, Gautam Patel, International Ltd Fosun, Jeffrey P George, John Kiely, Joseph Todisco, Paul M Meister, Pradeep Bhadauria, and Ted C Nark.
View insider buying and selling activity for Amneal Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Amneal Pharmaceuticals?

Shares of AMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amneal Pharmaceuticals' stock price today?

One share of AMRX stock can currently be purchased for approximately $5.24.

How much money does Amneal Pharmaceuticals make?

Amneal Pharmaceuticals has a market capitalization of $1.58 billion and generates $1.99 billion in revenue each year. The company earns $91.06 million in net income (profit) each year or $0.52 on an earnings per share basis.

How many employees does Amneal Pharmaceuticals have?

Amneal Pharmaceuticals employs 6,000 workers across the globe.

What is Amneal Pharmaceuticals' official website?

The official website for Amneal Pharmaceuticals is www.amneal.com.

Where are Amneal Pharmaceuticals' headquarters?

Amneal Pharmaceuticals is headquartered at 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807.

How can I contact Amneal Pharmaceuticals?

Amneal Pharmaceuticals' mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The company can be reached via phone at 908-947-3120 or via email at [email protected]


This page was last updated on 6/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.